Dobesil500 mg

Dobesil 500 mg is a vasoprotective (angioprotective) agent used in the symptomatic treatment of the following conditions:

Established / Widely Approved Uses

• Chronic venous insufficiency (CVI): Dobesil 500 mg is used to relieve symptoms such as leg pain, heaviness, swelling (edema), night cramps, and discomfort associated with varicose veins and chronic venous disease of the lower limbs.

Guideline-Supported / Regionally Approved Adjunct Uses

• Hemorrhoidal disease: Dobesil 500 mg is used as an adjunct to relieve symptoms (pain, bleeding, discomfort) of acute hemorrhoidal episodes, generally alongside standard local measures and other treatments.
• Diabetic retinopathy (background/non-proliferative): In some countries, Dobesil 500 mg is used as an adjunct to reduce capillary hyperpermeability and slow progression of early-stage diabetic retinopathy. Evidence for this use is more limited and regionally variable compared to established first-line therapies (e.g., glycemic control, laser photocoagulation, anti-VEGF therapy), and Dobesil 500 mg should not replace standard diabetic eye care.

Note: Dobesil 500 mg is not approved by the US FDA and is not marketed in the United States; its use is based on approvals and clinical practice in Europe, Latin America, and parts of Asia.

Dobesil 500 mg is available as oral solid dosage forms, most commonly:

• Dobesil 500 mg 500 mg capsule/tablet
• Dobesil 500 mg 250 mg capsule (in some markets)

Each unit contains Dobesil 500 mg as the active pharmaceutical ingredient, along with standard pharmaceutical excipients.

Dobesil 500 mg is a synthetic angioprotective (capillary-protective) drug belonging to the venotonic/vasoprotective class of medicines. It is used mainly for the symptomatic management of chronic venous insufficiency and related microvascular conditions, and in some markets for hemorrhoids and early diabetic retinopathy.

Dobesil 500 mg works by improving capillary resistance and reducing abnormal capillary permeability, which helps reduce fluid leakage, edema, and the discomfort associated with venous and microvascular disorders.

Vasoprotective / Angioprotective agent (capillary-protecting and venotonic drug); Dobesil 500 mg is classified with agents used for chronic venous insufficiency.

Dobesil 500 mg is an angioprotective agent whose exact mechanism of action is not completely established, but several actions have been described:

• Reduction of capillary hyperpermeability: Dobesil 500 mg normalizes increased capillary permeability, reducing plasma leakage into surrounding tissue and thereby reducing edema.
• Increase in capillary resistance: It strengthens capillary walls, reducing fragility.
• Decrease in blood viscosity and platelet aggregation: Dobesil 500 mg has mild antiplatelet and rheological effects that may improve microcirculatory blood flow.
• Antioxidant effect: Dobesil 500 mg scavenges free radicals, which may contribute to protecting the retinal microvasculature in diabetic retinopathy.

These combined effects underlie the use of Dobesil 500 mg in conditions involving increased capillary fragility and permeability, such as chronic venous insufficiency and diabetic microangiopathy.

Dobesil 500 mg is taken orally. Capsules/tablets should be swallowed whole with a glass of water.

• Dobesil 500 mg may be taken with or without food, preferably with meals to minimize gastrointestinal discomfort.
• Doses should be spaced evenly through the day as directed by the physician.
• Do not crush or chew the capsule/tablet unless specifically advised.

Clinically significant interactions with Dobesil 500 mg include:

• Anticoagulants and antiplatelet agents (e.g., warfarin, aspirin, clopidogrel): Dobesil 500 mg has mild antiplatelet activity; concurrent use may theoretically increase the risk of bleeding. Monitor patients on combined therapy.
• Other drugs associated with blood dyscrasias: Because rare cases of agranulocytosis have been reported with Dobesil 500 mg (see Precautions and Warnings), caution is advised when co-administering other medicines known to affect bone marrow function, due to potential additive hematologic risk.

No other well-established, clinically significant drug interactions with Dobesil 500 mg have been documented. Patients should inform their physician of all medicines they are taking before starting Dobesil 500 mg.

Dobesil 500 mg is generally well tolerated at recommended doses. Reported side effects include:

Common

• Nausea
• Diarrhea or other mild gastrointestinal upset
• Headache

Uncommon

• Skin rash
• Dizziness
• Fever

Rare but Serious

• Agranulocytosis: Rare but serious reports of agranulocytosis (a severe drop in white blood cells) have been associated with Dobesil 500 mg use. Patients should seek prompt medical attention if they develop fever, sore throat, mouth ulcers, or other signs of infection while taking Dobesil 500 mg (see Precautions and Warnings).
• Elevated liver enzymes (rare, reversible on discontinuation)

Safety data for Dobesil 500 mg use during pregnancy and lactation are limited. Dobesil 500 mg should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. It is advisable to avoid Dobesil 500 mg during the first trimester unless specifically directed by a physician.

It is not established whether Dobesil 500 mg passes into breast milk. Use during breastfeeding should only occur after consulting a physician, who will weigh the benefits of treatment against any potential risk to the infant.

The following precautions should be observed with Dobesil 500 mg:

• Agranulocytosis risk: Rare but serious cases of agranulocytosis have been reported with Dobesil 500 mg. Patients should be advised to report any signs of infection, unexplained fever, or sore throat promptly to their physician. If agranulocytosis is suspected, Dobesil 500 mg should be discontinued immediately and appropriate medical care sought.
• Limited efficacy evidence for diabetic retinopathy: The evidence supporting use of Dobesil 500 mg in diabetic retinopathy is more limited and variable compared to established first-line therapies. Dobesil 500 mg should be used as an adjunct only, and patients should continue standard diabetic eye care and monitoring.
• Bleeding risk: Use with caution in patients on anticoagulant or antiplatelet therapy (see Interactions).
• Hepatic monitoring: Periodic monitoring of liver function may be considered with prolonged use, given rare reports of elevated liver enzymes.

Limited data are available on overdose with Dobesil 500 mg. In the event of a suspected overdose, seek immediate medical attention or contact a poison control center. Treatment of overdose with Dobesil 500 mg should be symptomatic and supportive, managed by qualified medical personnel; there is no specific antidote for Dobesil 500 mg. Do not attempt to manage an overdose at home.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal impairment: There is limited specific dosing data for Dobesil 500 mg in renal impairment; use with caution and physician supervision.

Hepatic impairment: Use Dobesil 500 mg with caution in patients with hepatic impairment, given rare reports of liver enzyme elevation; monitor liver function if used long-term.

Elderly: No specific dose adjustment of Dobesil 500 mg is established for elderly patients, but they should be monitored for tolerability.

Pediatric patients: Safety and efficacy of Dobesil 500 mg have not been established in children; its use in this population is not recommended (see Pediatric Uses).

The duration of treatment with Dobesil 500 mg depends on the condition being treated and the patient's response. For chronic venous insufficiency, courses of several weeks to a few months are typical, with re-evaluation by the physician to assess continued need. For acute hemorrhoidal episodes, shorter courses are generally used. Treatment should not be continued indefinitely without periodic medical review.

Angioprotective agents; Vasoprotectives and venotonics; capillary-protecting drugs (the class to which Dobesil 500 mg belongs).

Dobesil 500 mg acts by reducing capillary hyperpermeability and increasing capillary resistance, decreasing blood viscosity and platelet aggregation, and exerting antioxidant (free-radical scavenging) effects. Together, these actions reduce microvascular leakage and improve microcirculatory function, which underlies the therapeutic effects of Dobesil 500 mg in venous and capillary disorders.

The safety and efficacy of Dobesil 500 mg have not been established in pediatric patients. Dobesil 500 mg is not recommended for use in children, and no pediatric dosing regimen has been established.